Early Increase in Blood Flow (EIBS) in the Duodenum in Patients With Pancreatic Cancer
| Status: | Completed |
|---|---|
| Conditions: | Cancer, Cancer, Pancreatic Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 10/21/2012 |
| Start Date: | June 2010 |
| End Date: | October 2012 |
| Contact: | Michael B Wallace, MD |
| Email: | wallace.michael@mayo.edu |
| Phone: | 904-953-2000 |
Detectable Early Increase in Blood Flow (EIBS) in the Duodenum in Patients With Pancreatic Cancer
The investigators are testing a device called 4D-ELF. The device used in this study is
considered investigational, which means it has either not been approved by the Food and Drug
Administration (FDA) for routine clinical use or for the use described in this study.
However the FDA has allowed the use of this device in this research study.
During your endoscopy ultrasound, the new optic probe will be inserted inside the endoscope
and advanced to the tip of the endoscope prior to the scope being withdrawn. As the scope is
getting withdrawn, the light optic probe will be used to examine approximately 5 sections of
the small bowel. The probe will be gently placed against the lining of the small bowel and
each reading takes less than a second to record.
The overall goal of this study is to test a technique that in the future may allow
endoscopic detection of pancreatic neoplasia. The study is a single group, prospective,
open label pilot study designed to assess the feasibility and efficacy of 4D-ELF in
detecting EIBS in peri-ampullary duodenal mucosa in pancreatic cancer patients compared to
control patients. The expected duration of subject participation, and a description of the
sequence and duration of all trial periods, including follow-up is complete after the
initial evaluation.
Inclusion Criteria:
- Age 18 years or older.
- Informed written consent.
- Patient scheduled for previously planned EUS or ERCP.
- Patients with known adenocarcinoma of the pancreas.
Exclusion Criteria:
- Presence of conditions not allowing biopsy or FNA if clinically indicated (e.g.
coagulation disorder).
- Significant family history of pancreatic cancer.
- Patients with other tumors of the pancreas or duodenum (i.e neuroendocrine tumors,
carcinoid, GIST, known familial polyposis syndrome (FAP, HNPCC, Juvenile polyposis,
etc)).
- Patient with premalignant lesions (duodenal adenoma, IPMN).
- Active duodenitis/ulcer from any cause (peptic, H pylori etc).
- Patients with known chronic pancreatitis will be excluded from study group (not
control group however).
- Know pregnancy or sexually active females of childbearing age who are not practicing
an accepted form of birth control.
We found this trial at
1
site
Mayo Clinic Mayo Clinic's campus in Arizona provides medical care for thousands of people from...
Click here to add this to my saved trials
